- Home
- BIIB vs BAX Comparison
BIIB vs BAX Comparison
Compare BIIB & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- BAX
- Stock Information
- Founded
- BIIB 1978
- BAX 1931
- Country
- BIIB United States
- BAX United States
- Employees
- BIIB N/A
- BAX N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- BAX Medical/Dental Instruments
- Sector
- BIIB Health Care
- BAX Health Care
- Exchange
- BIIB Nasdaq
- BAX Nasdaq
- Market Cap
- BIIB 18.8B
- BAX 15.7B
- IPO Year
- BIIB 1991
- BAX N/A
- Fundamental
- Price
- BIIB $134.15
- BAX $30.85
- Analyst Decision
- BIIB Buy
- BAX Buy
- Analyst Count
- BIIB 26
- BAX 8
- Target Price
- BIIB $194.95
- BAX $37.25
- AVG Volume (30 Days)
- BIIB 1.7M
- BAX 3.3M
- Earning Date
- BIIB 07-31-2025
- BAX 05-01-2025
- Dividend Yield
- BIIB N/A
- BAX 2.20%
- EPS Growth
- BIIB 26.39
- BAX N/A
- EPS
- BIIB 10.12
- BAX N/A
- Revenue
- BIIB $9,816,400,000.00
- BAX $10,771,000,000.00
- Revenue This Year
- BIIB N/A
- BAX $8.06
- Revenue Next Year
- BIIB N/A
- BAX $4.19
- P/E Ratio
- BIIB $13.31
- BAX N/A
- Revenue Growth
- BIIB 1.59
- BAX 15.36
- 52 Week Low
- BIIB $110.04
- BAX $26.25
- 52 Week High
- BIIB $238.00
- BAX $40.49
- Technical
- Relative Strength Index (RSI)
- BIIB 62.26
- BAX 52.67
- Support Level
- BIIB $129.61
- BAX $29.16
- Resistance Level
- BIIB $134.74
- BAX $31.04
- Average True Range (ATR)
- BIIB 3.10
- BAX 0.73
- MACD
- BIIB 0.60
- BAX -0.01
- Stochastic Oscillator
- BIIB 86.90
- BAX 68.70
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About BAX Baxter International Inc.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.